ARTL - MAXR AIMT among premarket gainers February, 03 2020 09:13 AM Artelo Biosciences Inc. Artelo Biosciences (NASDAQ:ARTL) +63% on NCI grant of $4.2M to Stony Brook University to advance FABP5 inhibitor cancer program.More news on: Artelo Biosciences, Inc., Insmed Incorporated, CTI BioPharma Corp., Stocks on the move, , Read more ...